Matrix metalloproteinase-10 effectively reduces infarct size in experimental stroke by enhancing fibrinolysis via a thrombin-activatable fibrinolysis inhibitor-mediated mechanism.

Orbe, J

Matrix metalloproteinase-10 effectively reduces infarct size in experimental stroke by enhancing fibrinolysis via a thrombin-activatable fibrinolysis inhibitor-mediated mechanism. [electronic resource] - Circulation Dec 2011 - 2909-19 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1524-4539

10.1161/CIRCULATIONAHA.111.047100 doi


Animals
Bleeding Time
Brain Ischemia--drug therapy
Carotid Artery Diseases--drug therapy
Cerebral Hemorrhage--metabolism
Cerebral Infarction--drug therapy
Disease Models, Animal
Extracellular Matrix--metabolism
Female
Fibrinolysis--drug effects
Fibrinolytic Agents--pharmacology
Humans
Intracranial Thrombosis--drug therapy
Male
Matrix Metalloproteinase 10--genetics
Mice
Mice, Inbred C57BL
Mice, Mutant Strains
Stroke--drug therapy
Thrombin--metabolism
Tissue Plasminogen Activator--pharmacology